VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Cardiovascular Events in Patients with Compromised Renal Function at Baseline in Prespecified and Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at American Society of Nephrology (ASN) Kidney Week 2020

Suma Ramadas, PhD
Medical Affairs

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy